On July 22, Avalere experts discussed the marketplace for COVID-19 vaccines and therapeutics in the “Cutting Through the Noise: Market Evolution and Pathways to Access for COVID-19 Vaccines and Therapeutics” webinar. They examined FDA regulatory considerations, coverage and access challenges, and key pricing and distribution scenarios for optimal US market access.
Tune into another episode of Start Your Day with Avalere. In this segment, experts from our vaccines team discuss the general outlook for the vaccines marketplace and pipeline.
Hafez expands Avalere's market access capabilities with deep expertise in strategy, operations, commercialization, and analytics.
Tune into our first episode of the Avalere Health Essential Voice: Social Determinants of Health (SDOH) series. In this segment, Avalere experts from the Center for Healthcare Transformation and the Health Plans and Providers practice set the stage for how stakeholders are defining SDOH and the impacts of SDOH on health outcomes, specifically when addressing social risks and needs.
Avalere is releasing a new research agenda to guide evidence generation for health system models of care that advance the intersection of social and clinical needs of Medicaid-eligible individuals.
Vaccine development is at the forefront of global efforts to address the COVID-19 pandemic, with a rapidly growing pipeline of candidates that will expand the existing vaccine landscape.
Avalere’s 2020 Election series started with our experts covering the current state of play in the 2020 election and the role of healthcare between now and November.
He brings healthcare tech, data, advocacy, and strategy experience to the firm.
As businesses across the country begin to reopen, navigating the COVID-19 pandemic will continually require employers to be resilient, flexible, innovative, and forward looking when it comes to returning employees safely to work sites. Among the myriad of concerns and considerations, organizational leadership will need tools that assist decision making and ensure compliance with Centers for Disease Control and Prevention (CDC) guidance.
New analysis of trade data finds that 54% of API, in dollars, used in domestically consumed medicines came from the US in 2019.
Affordable Care Act (ACA) exchanges have seen a significant uptick in enrollment, especially from those losing employer-sponsored coverage or who were previously uninsured. However, different approaches to special enrollment periods (SEPs) leave many with limited opportunities to enroll.
She deepens the firm’s post-acute and policy analytics capabilities, bringing nearly 15 years' worth of policy analytics experience to Avalere with a specific focus on the provider sector.
After adjourning or suspending sessions due to the COVID-19 pandemic, state legislatures are reconvening with new priorities, as pandemic-related policy decisions take precedence.
Tune into part 3 of our tenth episode of Avalere Health Essential Voice podcast series. In this segment, Avalere experts from the Center for Healthcare Transformation will discuss the impacts of the COVID-19 pandemic on provider performance-based incentive programs.
Though Americans have been encouraged to physically distance themselves to minimize transmission of COVID-19, individuals who are homeless or living in institutional settings may not be able to adhere to these guidelines, putting them at higher risk of contracting and transmitting the virus.
Avalere experts discussed the marketplace for COVID-19 vaccines and therapeutics, including key decision points for regulatory pathways, pricing, and distribution scenarios for optimal US and EX-US market access.
Tune into part 2 of our tenth episode of Avalere Health Essential Voice podcast series. In this segment, Avalere experts from the Center for Healthcare Transformation will discuss the impacts of COVID-19 on healthcare provider performance specific to exemptions and waivers.
On June 11, Avalere experts explored the future of telehealth and how organizations can help shape and take advantage of its increased utilization.
With the release of the 2021 Medicare Advantage (MA) and Part D Final Rule, the details of the upcoming policy change that allows beneficiaries with end-stage renal disease (ESRD) to enroll in MA are set. Stakeholders need to adapt quickly to be prepared.
Deferral of care during the COVID-19 pandemic is resulting in fewer claims and diagnoses among Medicare Advantage (MA) enrollees, which could lead to a 3%–7% reduction in 2021 risk scores and lower plan payments in 2021.
